新型生物制剂相关急性肾损伤的诊治进展

Advances in treatment of acute kidney injury induced by novel biological agents

新型生物制剂相关的肾毒性报道日益增多。研究表明,免疫检查点抑制剂、血管内皮生长因子通路抑制剂、小分子蛋白激酶抑制剂和肿瘤坏死因子α抑制剂等临床一线生物制剂可能会诱导急性肾损伤(acute kidney injury,AKI)的发生。这些药物造成肾脏损害的情况及相关机制有所不同,目前也仍然缺乏相关的实践指南或专家共识。本文就近年来新型生物制剂相关性急性肾损伤的发生情况及诊治进展进行综述,以期为临床诊疗提供新思路。

Nephrotoxicity associated with novel biological agents has been increasingly reported.Studies had shown that numerous commonly-used biological agents such as immune checkpoint inhibitors,vascular endothelial growth factor inhibitors,small molecule protein kinase inhibitors,tumor necrosis factor-α inhibitor could induce acute kidney injury(AKI).The kidney injury caused by distinct biological agents and mechanisms are diverse,and there is still a lack of practice guidelines or expert consensus.In this paper,we reviewed the advances in occurrence and treatment of AKI related to novel biological agents in recent years.